RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer - Test2 - elhamkhani - TriplyDB

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

http://www.wikidata.org/entity/Q27657185

about

Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction Novel agents for advanced pancreatic cancer MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK Crystal structure of non-phosphorylated MAP2K6 in a putative auto-inhibition state Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Sustained induction of collagen synthesis by TGF-β requires regulated intramembrane proteolysis of CREB3L1 EGF receptor is required for KRAS-induced pancreatic tumorigenesis KB-Rank: efficient protein structure and functional annotation identification via text query Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK.From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.Chiral kinase inhibitors.MEK and the inhibitors: from bench to bedside.Arbitrary protein-protein docking targets biologically relevant interfaces.Use of kinase inhibitors to correct ΔF508-CFTR function.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.BAMBI regulates angiogenesis and endothelial homeostasis through modulation of alternative TGFβ signaling.Activation of the MEK-S6 pathway in high-grade ovarian cancers.Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.A novel role for copper in Ras/mitogen-activated protein kinase signaling.Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model.Novel mitogen-activated protein kinase kinase inhibitors.MEK inhibitors: a patent review 2008 - 2010.Mucin as a therapeutic target in pseudomyxoma peritonei.MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.Prospects for MEK inhibitors for treating cancer.

P2860

Q24622527-5B8DBE9A-FCA1-41CF-B66A-8A2A18B50D68 Q26787087-4A40A2B7-2E95-4A7D-A4B1-DF95177F7FAE Q27335195-82A2C70A-1680-4F5B-A0C5-48CB152C75F2 Q27667127-D9900C8E-C34D-464A-9A50-A2696CC44B6A Q27677567-4BFC37C0-CD01-4367-AD94-46A088905753 Q28075305-4BB00F84-03FC-4956-8E5B-9DD0EC0F5C03 Q28117988-637AF52B-2DE4-4227-ADA9-B5E7BF96BF6E Q28584901-C8C13D6A-E162-4931-A1F2-B8B6CE392227 Q28728482-34720056-7569-4B13-8118-3BA96DB8DC3E Q30313606-B4DD5572-02A4-420A-A4AE-C18F91AAB309 Q33555365-ACB8F30B-CD5D-447D-B3E5-6C165B839199 Q33698374-DB4659C6-7F0F-4106-AD70-24FB328188A0 Q33709656-C38AE322-7797-4155-9780-C1596ED2ED0A Q33756524-88745785-52B0-4DD8-8D9F-E8162AA00905 Q33811207-CE6D6B0F-7C1B-4FD6-9D6F-CF5712BCEB97 Q34036341-2A6E7DB0-2FE1-44C5-BA25-0BAC4E84B4C2 Q34257699-374DD3A3-1747-4E5B-AE6C-C3199E4CFC60 Q34304720-FBB3E2C8-435D-4A6B-82DA-5A33D03BE862 Q34307356-A5C8409B-B987-45E5-B33C-8CFCE600878D Q34326101-46D4DCB1-F396-421A-8648-77319894F001 Q34339010-95D03A36-B567-4940-B52C-A611CC052266 Q34403458-B3E832A8-65C5-4793-A842-4CF01C5ACA07 Q35034373-648D05DA-872C-4E32-92D3-62E16C028FA6 Q35379875-1AB522ED-6101-429F-B1EB-02CC0390A833 Q35501246-A60D423D-5A7E-472F-9D01-ED3808275F49 Q35679353-D17701EA-C858-45E6-B2FF-77809C019CE0 Q35691935-3E0C9E1A-FF48-485D-B337-8E05D7F4ED9F Q35826693-CB6D862C-449D-4B22-9678-9AACD185F45B Q35891699-2C91AC58-75A9-4E20-972C-92EB5BDA1995 Q36278239-7EDB5B78-631D-43FB-B5E9-F169452FF9FE Q36328021-2713120C-A221-4E0D-9371-7218BC87B133 Q36813976-3923E050-E305-4F81-BC58-39D4355A89B5 Q37285551-F7E133D4-9696-4BF7-8ED5-7F092121C454 Q37339708-6AB24C7E-134A-475E-9AFF-BF8AB82080EA Q37699643-E0900C75-56DC-44DB-8D48-06A3763CAB21 Q37828536-02F8B596-7B65-411C-BD64-EBAA1806D4C4 Q37872791-4A74257A-234B-4BD9-814F-2A66D394E233 Q38010127-2F0C81F6-6D2F-4758-BA48-6350AE4F5096 Q38092584-C8694CD8-ED6A-4863-84E3-376159D5F4C5 Q38193520-9CCA4E49-C246-4D5E-BE8D-94827CF9414E

P2860

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

http://www.wikidata.org/entity/Q27657185

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@ast

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@en

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@nl

type

label

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@ast

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@en

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@nl

prefLabel

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@ast

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@en

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@nl

P1433

Q27657185-BD3E3CCB-A5EE-4967-9565-01E2FF5B5CB2

P1476

Q27657185-875C689C-6E21-4FAC-9807-03C9720E7975

P2093

Q27657185-1C145FC4-61B7-4D67-B021-5FA7506ACA1F

Q27657185-1EDE5A4C-CE96-4D24-B1BB-575123CDCA59

Q27657185-29D1E415-7834-4F3B-B846-8CA1D2D963A8

Q27657185-37114637-C3A5-4710-A142-41104DB5DC23

Q27657185-40A6D5E5-63A4-4E10-B33E-721D5E38D530

Q27657185-7854B241-6709-4EB3-B2D4-34432523B54F

Q27657185-8C02B45E-EA24-4CD5-B385-789EF8C6342D

Q27657185-8EC1A512-099E-4E34-BB0D-CE126F1563F2

Q27657185-A418FBB2-9122-4529-AFEE-A108DA5949BB

Q27657185-A71C65CE-795F-4D39-B692-B3E061406103

P304

Q27657185-615125BF-F1DD-4B0B-A9C8-9179793424D0

P31

Q27657185-DF093F50-CEFF-4326-BE67-16B7B82B2AA9

P3181

Q27657185-43DF9F26-99A9-4B32-AA5F-05B1AE86B459

P356

Q27657185-8C83426A-7032-48F0-A5CA-9AB43CEEC2C7

P407

Q27657185-F9558375-802A-409A-80A3-44C5935F7CAE

P433

Q27657185-7D3BBBD6-F2F6-4F23-97A3-14B71FE24325

P478

Q27657185-7AFCF07F-513F-48CD-9EED-A0575F91C177

P577

Q27657185-409E9262-6FE3-4DE9-B7EA-06E2400DF44A

P698

Q27657185-D9B50D91-3387-4246-AC25-0AC98E00FA5B

P921

Q27657185-55A17EBB-AAB2-4045-A180-D08B8BB5DCF8

P3181

P356

0008-5472.CAN-09-0679

P1433

Cancer Research

P1476

RDEA119/BAY 869766: a potent, ...... /2 for the treatment of cancer

@en

P2093

Andreas Maderna

http://www.w3.org/2001/XMLSchema#string

Barry Quart

http://www.w3.org/2001/XMLSchema#string

Chon Lai

http://www.w3.org/2001/XMLSchema#string

Claudia Dadson

http://www.w3.org/2001/XMLSchema#string

Cory Iverson

http://www.w3.org/2001/XMLSchema#string

Gary Larson

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Vernier

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Miner

http://www.w3.org/2001/XMLSchema#string

Li-Tain Yeh

http://www.w3.org/2001/XMLSchema#string

Paul Weingarten

http://www.w3.org/2001/XMLSchema#string

P304

6839-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2605102

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-09-0679

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19706763

http://www.w3.org/2001/XMLSchema#string

P921

allosteric inhibitor